Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

CUSIP: 761330109

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
104,661,494
Total 13F shares
81,357,406
Share change
-1,678,380
Total reported value
$209,091,543
Put/Call ratio
35%
Price per share
$2.57
Number of holders
167
Value change
-$16,845,100
Number of buys
86
Number of sells
80

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Capital World Investors
13F
Company
13%
13,945,535
$68,612,032 31 Mar 2024
13F
BlackRock Finance, Inc.
13F
Company
7%
7,312,479
$35,977,397 31 Mar 2024
13F
FRANKLIN RESOURCES INC
13F
Company
6%
6,283,407
$30,914,364 31 Mar 2024
13F
VANGUARD GROUP INC
13F
Company
5.2%
5,398,406
$26,560,157 31 Mar 2024
13F
Palo Alto Investors LP
13F
Company
5%
5,248,004
$25,820,180 31 Mar 2024
13F
Polar Capital Holdings Plc
13F
Company
3.7%
3,884,819
$19,113,309 31 Mar 2024
13F
JPMORGAN CHASE & CO
13F
Company
3%
3,153,123
$15,513,366 31 Mar 2024
13F
BARCLAYS PLC
13F
Company
2.9%
3,019,342
$14,855,162 31 Mar 2024
13F
Rubric Capital Management LP
13F
Company
2.5%
2,656,847
$13,071,687 31 Mar 2024
13F
STATE STREET CORP
13F
Company
2.3%
2,358,777
$11,605,183 31 Mar 2024
13F
Stonepine Capital Management, LLC
13F
Company
1.9%
1,976,342
$9,723,603 31 Mar 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
1.9%
1,970,838
$9,697,712 31 Mar 2024
13F
CIBC Asset Management Inc
13F
Company
1.7%
1,740,518
$8,563,349 31 Mar 2024
13F
SUVRETTA CAPITAL MANAGEMENT, LLC
13F
Company
1.5%
1,600,000
$7,872,000 31 Mar 2024
13F
FEDERATED HERMES, INC.
13F
Company
1.5%
1,564,702
$7,698,334 31 Mar 2024
13F
MORGAN STANLEY
13F
Company
1.2%
1,203,904
$5,923,213 31 Mar 2024
13F
BAMCO INC /NY/
13F
Company
0.98%
1,023,663
$5,036,422 31 Mar 2024
13F
Aubrey Rankin
3/4/5
Director
class O/S missing
570,004
$4,257,930 15 Mar 2022
NORTHERN TRUST CORP
13F
Company
0.83%
865,229
$4,256,927 31 Mar 2024
13F
Opaleye Management Inc.
13F
Company
0.75%
785,000
$3,862,200 31 Mar 2024
13F
MARSHALL WACE, LLP
13F
Company
0.75%
781,223
$3,843,617 31 Mar 2024
13F
RICE HALL JAMES & ASSOCIATES, LLC
13F
Company
0.71%
746,139
$3,671,004 31 Mar 2024
13F
Rhenman & Partners Asset Management AB
13F
Company
0.67%
701,707
$3,452,398 31 Mar 2024
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.67%
700,050
$3,444,246 31 Mar 2024
13F
Walleye Capital LLC
13F
Company
0.59%
622,126
$3,060,860 31 Mar 2024
13F
PERCEPTIVE ADVISORS LLC
13F
Company
0.57%
600,000
$2,952,000 31 Mar 2024
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.52%
543,449
$2,673,769 31 Mar 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.48%
504,676
$2,483,005 31 Mar 2024
13F
EULAV Asset Management
13F
Company
0.48%
500,000
$2,460,000 31 Mar 2024
13F
Sio Capital Management, LLC
13F
Company
0.45%
468,871
$2,306,845 31 Mar 2024
13F
Essex Woodlands Management, Inc.
13F
Company
0.44%
457,085
$2,248,858 31 Mar 2024
13F
Ghost Tree Capital, LLC
13F
Company
0.43%
450,000
$2,214,000 31 Mar 2024
13F
HighTower Advisors, LLC
13F
Company
0.43%
445,387
$2,192,000 31 Mar 2024
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.36%
373,700
$1,839,000 31 Mar 2024
13F
Nuveen Asset Management, LLC
13F
Company
0.34%
352,042
$1,732,047 31 Mar 2024
13F
BLAIR WILLIAM & CO/IL
13F
Company
0.31%
329,267
$1,619,994 31 Mar 2024
13F
Bank of New York Mellon Corp
13F
Company
0.29%
304,564
$1,498,455 31 Mar 2024
13F
D. E. Shaw & Co., Inc.
13F
Company
0.28%
298,110
$1,466,701 31 Mar 2024
13F
SCHRODER INVESTMENT MANAGEMENT GROUP
13F
Company
0.28%
288,726
$1,420,532 31 Mar 2024
13F
DCF Advisers, LLC
13F
Company
0.25%
263,372
$1,295,790 31 Mar 2024
13F
TWO SIGMA INVESTMENTS, LP
13F
Company
0.25%
257,397
$1,266,393 31 Mar 2024
13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
13F
Company
0.24%
254,667
$1,252,962 31 Mar 2024
13F
CM Management, LLC
13F
Company
0.24%
250,000
$1,230,000 31 Mar 2024
13F
MOORE CAPITAL MANAGEMENT, LP
13F
Company
0.24%
250,000
$1,230,000 31 Mar 2024
13F
AlphaCentric Advisors LLC
13F
Company
0.23%
245,000
$1,205,400 31 Mar 2024
13F
Mirae Asset Global Investments Co., Ltd.
13F
Company
0.04%
37,618
$1,111,531 31 Mar 2024
13F
ESSEX INVESTMENT MANAGEMENT CO LLC
13F
Company
0.21%
220,160
$1,083,187 31 Mar 2024
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0.2%
211,695
$1,041,539 31 Mar 2024
13F
TANG CAPITAL MANAGEMENT LLC
13F
Company
0.19%
200,000
$984,000 31 Mar 2024
13F
Assenagon Asset Management S.A.
13F
Company
0.19%
198,846
$978,322 31 Mar 2024
13F

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2024

As of 30 Jun 2024, Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by 167 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 81,357,406 shares. The largest 10 holders included Capital World Investors, BlackRock Inc., FRANKLIN RESOURCES INC, VANGUARD GROUP INC, Palo Alto Investors LP, Polar Capital Holdings Plc, JPMORGAN CHASE & CO, Stonepine Capital Management, LLC, Rubric Capital Management LP, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 168 institutional shareholders reporting positions in this security for the Q2 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
182
Q2 2024 holders
167
Holder diff
-15
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 Value $ Q2 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.